PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0700
0.00 (0.00%)
Jun 26, 2026, 9:30 AM EST
PURE Bioscience Income Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
| 2.42 | 2.2 | 1.96 | 1.88 | 1.85 | 3.93 | |
Revenue Growth (YoY) | 26.67% | 12.17% | 4.58% | 1.29% | -52.81% | -43.23% |
Cost of Revenue | 1 | 0.9 | 0.81 | 0.91 | 0.85 | 1.85 |
Gross Profit | 1.43 | 1.3 | 1.15 | 0.97 | 1 | 2.08 |
Selling, General & Admin | 3.03 | 3.26 | 3.98 | 4.3 | 4.05 | 4.05 |
Research & Development | 0.31 | 0.32 | 0.3 | 0.3 | 0.32 | 0.34 |
Operating Expenses | 3.34 | 3.58 | 4.28 | 4.6 | 4.37 | 4.39 |
Operating Income | -1.92 | -2.27 | -3.13 | -3.63 | -3.37 | -2.31 |
Interest Expense | -0.39 | -0.3 | -0.16 | -0.01 | -0.01 | -0 |
Other Non Operating Income (Expenses) | 0.18 | 0.17 | -0 | -0 | - | -0 |
EBT Excluding Unusual Items | -2.12 | -2.4 | -3.29 | -3.65 | -3.38 | -2.32 |
Asset Writedown | - | - | -0.06 | -0.32 | -0.35 | - |
Other Unusual Items | -0.08 | - | - | - | 0.24 | - |
Pretax Income | -2.21 | -2.4 | -3.35 | -3.96 | -3.49 | -2.32 |
Net Income | -2.21 | -2.4 | -3.35 | -3.96 | -3.49 | -2.32 |
Net Income to Common | -2.21 | -2.4 | -3.35 | -3.96 | -3.49 | -2.32 |
Shares Outstanding (Basic) | 112 | 112 | 112 | 111 | 89 | 87 |
Shares Outstanding (Diluted) | 112 | 112 | 112 | 111 | 89 | 87 |
Shares Change (YoY) | -0.20% | 0.01% | 0.41% | 25.41% | 1.91% | 3.03% |
EPS (Basic) | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 | -0.03 |
EPS (Diluted) | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 | -0.03 |
Free Cash Flow | -1.78 | -2.02 | -2.53 | -3.31 | -2.5 | -1.69 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 |
Gross Margin | 58.84% | 59.17% | 58.69% | 51.73% | 53.97% | 52.84% |
Operating Margin | -79.11% | -103.18% | -159.50% | -193.29% | -181.87% | -58.85% |
Profit Margin | -91.04% | -108.95% | -170.66% | -211.03% | -188.40% | -59.05% |
Free Cash Flow Margin | -73.49% | -91.51% | -128.94% | -176.40% | -134.86% | -42.98% |
EBITDA | -1.91 | -2.27 | -2.98 | -3.51 | -3.16 | -2.14 |
EBITDA Margin | -79.03% | -103.09% | -151.96% | -187.05% | -170.37% | -54.47% |
D&A For EBITDA | 0 | 0 | 0.15 | 0.12 | 0.21 | 0.17 |
EBIT | -1.92 | -2.27 | -3.13 | -3.63 | -3.37 | -2.31 |
EBIT Margin | -79.11% | -103.18% | -159.50% | -193.29% | -181.87% | -58.85% |
Revenue as Reported | 2.42 | 2.2 | 1.96 | 1.88 | 1.85 | 3.93 |